6-(chloromethyl)picolinic acid | 49715-22-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(chloromethyl)picolinic acid
• 英文别名: 2-Pyridinecarboxylic acid, 6-(chloromethyl)-；6-(chloromethyl)pyridine-2-carboxylic acid
• CAS: 49715-22-2
• 化学式: C₇H₆ClNO₂
• 分子量: 171.583
• InChiKey: RSHQMUWHPKLSSO-UHFFFAOYSA-N

物化性质

• 沸点：
  345.6±32.0 °C(Predicted)
• 密度：
  1.396±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(chloromethyl)picolinic acid 、 对氯苯酚 在 aluminum (III) chloride 作用下， 反应 6.0h， 生成 6-[(5-chloro-2-hydroxyphenyl)methyl]-2-pyridinecarboxylic acid
  参考文献：
  名称：

  Selection and Development of the Manufacturing Route for EP₁ Antagonist GSK269984B

  摘要：

  A potential manufacturing route for the EP1 antagonist GSK269984B was developed. Four synthetic approaches were examined, and a successful realisation of each is presented. The rationale supporting selection of the preferred route is discussed. This route utilised a phenolic aldol reaction as the key step and relied on selective hydrogenolysis to reduce an intermediate diarylmethanol. Further optimisation of the selected route is presented, delivering GSK269984B in three stages and 46% overall yield from readily available starting materials.

  DOI：

  10.1021/op100072y
• 作为产物：
  描述：

  6-氯甲基-2-吡啶羧酸甲酯 在 水 、 lithium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以441 mg的产率得到6-(chloromethyl)picolinic acid
  参考文献：
  名称：

  [EN] OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS
  [FR] DÉRIVÉS D'OXOPYRIDINE UTILES EN TANT QU'INHIBITEURS DE LA SEMIALDÉHYDE DÉCARBOXYLASE D'AMINOCARBOXYMUCONATE (ACMSD)

  摘要：

  公开号：

  WO2018125983A8

文献信息

• Compounds and methods for inhibiting phosphate transport
  申请人：Ardelyx, Inc.

  公开号：US09301951B2

  公开（公告）日：2016-04-05

  Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, A, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  揭示了具有磷酸盐转运抑制活性的化合物，更具体地说，是肠道顶端膜Na/磷酸盐共转运的抑制剂。这些化合物具有以下结构（I）： 包括立体异构体、药用可接受的盐和前药，其中X、Y、A、R1和R2如本文所定义。还公开了与制备和使用这些化合物相关的方法，以及包含这些化合物的药物组合物。
• REINFORCED MACROCYCLIC LIGANDS, COMPLEXES THEREOF, AND USES OF SAME
  申请人：GUERBET

  公开号：US20200157101A1

  公开（公告）日：2020-05-21

  Ligands that are based on the pyclen macrocycle that are reinforced, which are useful for complexing elements such as radioelements and/or elements with magnetic properties.

  基于pyclen大环的配体被加固，对于络合放射性元素和/或具有磁性属性的元素是有用的。
• [EN] COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR L'INHIBITION DU TRANSPORT DE PHOSPHATE
  申请人：ARDELYX INC

  公开号：WO2012006473A1

  公开（公告）日：2012-01-12

  Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  具有磷酸盐转运抑制活性的化合物，更具体地说，披露了对肠道顶膜Na/磷酸盐共转运的抑制剂。这些化合物具有以下结构（I）：包括立体异构体、药用可接受的盐及其前药，其中X、Y和A如本文所定义。还披露了与制备和使用这类化合物相关的方法，以及包含这类化合物的药物组合物。
• MACROCYLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND ALSO MEDICAL USES THEREOF
  申请人：GUERBET

  公开号：US20190023705A1

  公开（公告）日：2019-01-24

  The present invention relates to compounds, ligands, and/or complexes that are useful in medical imaging and/or in therapy, especially in cancer treatment. The present invention also relates to a pharmaceutical composition comprising said compounds, ligands, and/or complexes that are useful for medical imaging, targeting, and/or treatment of cancers. The present invention also relates to a process for preparing these compounds, ligands, and/or complexes.

  本发明涉及在医学成像和/或治疗中有用的化合物、配体和/或络合物，特别是在癌症治疗中有用的化合物、配体和/或络合物。本发明还涉及一种包含上述化合物、配体和/或络合物的药物组合物，用于医学成像、靶向和/或治疗癌症。本发明还涉及一种制备这些化合物、配体和/或络合物的方法。
• Method for Obtaining Highly Luminescent Lanthanide Complexes
  申请人：Mazzanti Marinella

  公开号：US20080227962A1

  公开（公告）日：2008-09-18

  The invention concerns a transition metal coordination complex of general formula (I) [M(X)]C(H 2 O)n}p wherein: M represents an element belonging to the lanthanide group; and L represents a decadentate chromophore ligand of general formula (II). R1, R2, R3 and R4 independently represent hydrogen or an alkyl or aryl radical. A1, A2, A3 and A4 independently represent a structure of general formula (III). U1, U2 and U3 independently represent C or N, and R5, R6 and R7 independently represent hydrogen, an alkyl or aryl radical. Y represents C, O, S, P or N, and m is an integer representing free valences of Y. R8 represents independently hydrogen, an alkyl or aryl radical. X represents a counter-ion, and n represents hydrating water molecules. p represents monomers. H 2 O represents the hydrating water molecules. The invention also concerns a method for preparing such a ligand.

  该发明涉及一种一般式(I) [M(X)]C(H2O)n}p 的过渡金属配位络合物，其中：M代表属于镧系元素的元素；L代表一种一般式(II)的十齿色团配体。R1、R2、R3和R4独立地代表氢或烷基或芳基基团。A1、A2、A3和A4独立地代表一种一般式(III)的结构。U1、U2和U3独立地代表C或N，R5、R6和R7独立地代表氢、烷基或芳基基团。Y代表C、O、S、P或N，m是表示Y的自由价的整数。R8独立地代表氢、烷基或芳基基团。X代表一个对离子，n代表水合水分子。p代表单体。H2O代表水合水分子。该发明还涉及一种制备这种配体的方法。